Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02JAY
|
|||
| Former ID |
DCL000237
|
|||
| Drug Name |
Stannsoporfin
|
|||
| Synonyms |
SNMPP; Stanate; Sn Mesoporphyrin; Tin mesoporphyrin; Stanate (TN); Stannsoporfin (USAN/INN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neonatal hyperbilirubinemia [ICD-11: KA87] | Phase 2 | [1] | |
| Company |
InfaCare Pharma.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H36Cl2N4O4Sn
|
|||
| Canonical SMILES |
[H+].[H+].CCC1=C(C2=NC1=CC3=C(C(=C([N-]3)C=C4C(=C(C(=CC5=NC(=C2)C(=C5C)CC)[N-]4)C)CCC(=O)[O-])CCC(=O)[O-])C)C.[Cl-].[Cl-].[Sn+4]
|
|||
| InChI |
1S/C34H38N4O4.2ClH.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;;/h13-16H,7-12H2,1-6H3,(H4,35,36,37,38,39,40,41,42);2*1H;/q;;;+4/p-4
|
|||
| InChIKey |
LLDZJTIZVZFNCM-UHFFFAOYSA-J
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Heme oxygenase 1 (HMOX1) | Target Info | Inhibitor | [2] |
| BioCyc | Heme degradation | |||
| KEGG Pathway | Porphyrin and chlorophyll metabolism | |||
| HIF-1 signaling pathway | ||||
| Mineral absorption | ||||
| MicroRNAs in cancer | ||||
| Pathwhiz Pathway | Porphyrin Metabolism | |||
| Pathway Interaction Database | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Iron uptake and transport | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01887327) Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates With Hyperbilirubinemia. U.S. National Institutes of Health. | |||
| REF 2 | Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol. 2004 Oct;28(5):365-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.